🏛️ Verified NIH Record • Updated 2026-08-27

A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread (NCT07543055)

🟢 Recruiting Phase1 📋 Clinical Research Protocol Sponsor: Regeneron Pharmaceuticals

🩺 Plain-English Summary (8th-Grade Level)

This study will test a study drug called BPX-601, a CAR-T cell product manufactured from the patient's own T-cells, to see if it can help treat advanced prostate cancer. BPX-601 is a drug that is only used in clinical studies. The study is looking at: * What side effects BPX-601 might cause * What is the best dose of BPX-601 * How well BPX-601 may work to destroy prostate cancer

Who can join: Review the eligibility criteria below.

Location: John Theurer Cancer Center — Hackensack, New Jersey

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (2 Sites)

  • John Theurer Cancer Center — Hackensack, New Jersey
  • Providence Portland Medical Center - Oncology — Portland, Oregon

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗